Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566772 · ClinicalTrials.gov registry record · Phase 1
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
NCT02566772 is a Phase 1 study that has completed, run by Taiho Oncology. The registered enrollment target is 130 participants.
The verdict
NCT02566772, a Phase 1 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase) and to further evaluate safety and preliminary efficacy of TAS3681 at the MTD/recommended dose (Expansion Phase).
Interventions
- DRUG TAS3681
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2016-03 |
| Est. Completion | 2024-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02566772
The ClinicalTrials.gov registry entry for NCT02566772 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS3681 is the first listed.
NCT02566772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02566772 about?
NCT02566772 is a clinical study titled "Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer". The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase) and to further evaluate safety and preliminary efficacy of TAS3681 at the MTD/recommended dose (Expansion Phase).
What is the current status of trial NCT02566772?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2016-03. Estimated completion is 2024-04-26.
What interventions are being tested in trial NCT02566772?
The interventions under investigation include: TAS3681 (DRUG).
Who is sponsoring clinical trial NCT02566772?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.